Tegileridine for Postoperative Pain After Adolescent Scoliosis Surgery
Key facts
- Who runs it
- Peking Union Medical College Hospital
- Where
- China6 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 171 people, planned
- Started
- 8 Apr 2026
- Expected to end
- 30 Dec 2027
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Tegileridine
- morphine
- Record updated
- 13 October 2026
Who can take part
- Age
- 10 years to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Aged 10 years to less than 18 years
- Scheduled to undergo posterior spinal fusion (PSF) surgery for adolescent idiopathic scoliosis under general anesthesia
- American Society of Anesthesiologists (ASA) physical status classification I to III
- The participant and their parent or legal guardian voluntarily provide written informed consent prior to any study-related procedures
Who cannot take part
- Chronic use of opioid analgesics, or use of any long-acting analgesics within 48 hours prior to surgery (short-acting non-opioid analgesics are permitted but must be discontinued at least 12 hours preoperatively)
- History of severe cardiovascular or cerebrovascular disease, such as myocardial infarction, unstable angina, second-degree or higher atrioventricular block, NYHA Class III or higher heart failure, or stroke
- Known hypersensitivity to opioids or any component of the study drug formulation
- Severe cognitive impairment or uncontrolled psychiatric disorders (e.g., active schizophrenia) that preclude the patient's ability to comprehend the NRS or independently operate the patient-controlled analgesia (PCA) pump
- Diagnosis of neuromuscular scoliosis or presence of any other chronic pain condition that may interfere with postoperative pain assessment
- Baseline room-air oxygen saturation (SpO2) < 90% at rest, acute or severe bronchial asthma
- Known or suspected gastrointestinal obstruction, including paralytic ileus
- Planned postoperative admission to the intensive care unit (ICU)
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 10 and 17 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to see if a new pain medicine called Tegileridine is at least as effective as morphine (the standard treatment) for pain relief after spinal surgery in teenagers with scoliosis. This type of study is called a "non-inferiority" trial. The study will also carefully compare the safety of both medicines.
Read full original descriptionShow less
The main questions it aims to answer are:
Is Tegileridine no worse than morphine at controlling pain in the first 24 hours after surgery? How do the side effects (like sleepiness or nausea) of Tegileridine compare to those of morphine? Researchers will compare two different doses of Tegileridine against morphine. Neither the participants nor the doctors assessing them will know which medicine is being given.
Participants in this study will:
Receive one of the three pain medicine options through a pump (called a PCA pump) that they can control themselves after surgery.
Use the pump for up to 48 hours. Regularly rate their pain levels using a simple number scale. Have their health closely monitored by the study team during this time.
The 3 groups in the trial
- Tegileridine 20 μg/kg Loading Dose + 1 μg/kg PCATreatment being tested
Participants in this arm will receive an initial intravenous loading dose of 20 μg/kg Tegileridine upon transfer to the post-anesthesia care unit (PACU), immediately followed by postoperative patient-controlled analgesia (PCA). The PCA solution is prepared by diluting Tegileridine in normal saline to a total volume of 200 ml. The PCA pump is programmed to deliver a bolus dose of 1 μg/kg Tegileridine per activation, with a 10-minute lockout interval and no background infusion. PCA therapy will be maintained for at least 48 hours, barring any adverse events requiring discontinuation.
Treatment: Tegileridine
- Tegileridine 20 μg/kg Loading Dose + 2 μg/kg PCATreatment being tested
Participants in this arm will receive an initial intravenous loading dose of 20 μg/kg Tegileridine upon transfer to the post-anesthesia care unit (PACU), immediately followed by postoperative patient-controlled analgesia (PCA). The PCA solution is prepared by diluting Tegileridine in normal saline to a total volume of 200 ml. The PCA pump is programmed to deliver a bolus dose of 2 μg/kg Tegileridine per activation, with a 10-minute lockout interval and no background infusion. PCA therapy will be maintained for at least 48 hours, barring any adverse events requiring discontinuation.
Treatment: Tegileridine
- Morphine 60 μg/kg Loading Dose + 20 μg/kg PCAExisting treatment, for comparison
Participants in this arm will receive an initial intravenous loading dose of 60 μg/kg morphine upon transfer to the post-anesthesia care unit (PACU), immediately followed by postoperative patient-controlled analgesia (PCA). The PCA solution is prepared by diluting morphine in normal saline to a total volume of 200 ml. The PCA pump is programmed to deliver a bolus dose of 20 μg/kg morphine per activation, with a 10-minute lockout interval and no background infusion. PCA therapy will be maintained for at least 48 hours, barring any adverse events requiring discontinuation.
Treatment: morphine
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy and Safety of Tegileridine on Postoperative Pain in Adolescent Patients Undergoing Scoliosis Correction Surgery: A Multicentre, Double-blind, Non-inferiority, Randomised Controlled Trial
- Criteria questions
- Built from NCT07229495, who can take part
- Record updated
- 13 October 2026